Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2016

Open Access 01-12-2016 | Research

Impact of metabolic syndrome on lipid target achievements in the Arabian Gulf: findings from the CEPHEUS study

Authors: Ibrahim Al-Zakwani, Wael Al Mahmeed, Abdullah Shehab, Mohamed Arafah, Ali T. Al-Hinai, Omer Al Tamimi, Mahmoud Al Awadhi, Shorook Al Herz, Faisal Al Anazi, Khalid Al Nemer, Othman Metwally, Akram Alkhadra, Mohammed Fakhry, Hossam Elghetany, Abdel Razak Medani, Afzal Hussein Yusufali, Obaid Al Jassim, Omar Al Hallaq, Fahad Omar Ahmed S. Baslaib, Haitham Amin, Khalid Al-Waili, Khamis Al-Hashmi, Raul D. Santos, Khalid Al-Rasadi

Published in: Diabetology & Metabolic Syndrome | Issue 1/2016

Login to get access

Abstract

Background

The aim of this study was to determine the impact of metabolic syndrome (MetS) on lipid target achievements in the Arabian Gulf.

Methods

The centralized pan-middle east survey on the undertreatment of hypercholesterolemia (CEPHEUS) included 4171 high and very high atherosclerotic cardiovascular disease (ASCVD) risk patients from six Arabian Gulf countries. Analyses were performed using univariate statistics.

Results

The overall mean age was 57 ± 11 years, 41 % were females and 71 % had MetS. MetS patients were less likely to attain their HDL-C (34 vs. 79 %; P < 0.001), LDL-C (27 vs. 37 %; P < 0.001), non HDL-C (35 vs. 55 %; P < 0.001) and Apo B (35 vs. 54 %; P < 0.001) compared to those without MetS. Within the MetS cohort, those with very high ASCVD risk were less likely to attain their lipid targets compared to those with high ASCVD risk [HDL-C (32 vs. 41 %; P < 0.001), LDL-C (24 vs. 43 %; P < 0.001), non HDL-C (32 vs. 51 %; P < 0.001) and Apo B (33 vs. 40 %; P = 0.001)]. In those with MetS and very high ASCVD risk status, females were less likely to attain their HDL-C (27 vs. 36 %; P < 0.001), LDL-C (19 vs. 27 %; P < 0.001) and Apo B (30 vs. 35 %; P = 0.009) compared to males.

Conclusions

MetS was associated with low lipid therapeutic targets. Women and those with very high ASCVD risk were also less likely to attain their lipid targets in the Arabian Gulf.
Literature
1.
go back to reference Mabry RM, Reeves MM, Eakin EG, Owen N. Gender differences in prevalence of the metabolic syndrome in Gulf Cooperation Council Countries: a systematic review. Diabet Med. 2010;27:593–7.CrossRefPubMed Mabry RM, Reeves MM, Eakin EG, Owen N. Gender differences in prevalence of the metabolic syndrome in Gulf Cooperation Council Countries: a systematic review. Diabet Med. 2010;27:593–7.CrossRefPubMed
2.
go back to reference AlSuwaidi J, Zubaid M, El-Menyar AA, et al. Prevalence of the metabolic syndrome in patients with acute coronary syndrome in six middle eastern countries. J Clin Hypertens. 2010;12:890–9.CrossRef AlSuwaidi J, Zubaid M, El-Menyar AA, et al. Prevalence of the metabolic syndrome in patients with acute coronary syndrome in six middle eastern countries. J Clin Hypertens. 2010;12:890–9.CrossRef
3.
go back to reference Al-Rasadi K, Sulaiman K, Panduranga P, Al-Zakwani I. Prevalence, characteristics, and in-hospital outcomes of metabolic syndrome among acute coronary syndrome patients from Oman. Angiology. 2011;62:381–9.CrossRefPubMed Al-Rasadi K, Sulaiman K, Panduranga P, Al-Zakwani I. Prevalence, characteristics, and in-hospital outcomes of metabolic syndrome among acute coronary syndrome patients from Oman. Angiology. 2011;62:381–9.CrossRefPubMed
4.
go back to reference Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle aged men. JAMA. 2002;288:2709–16.CrossRefPubMed Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle aged men. JAMA. 2002;288:2709–16.CrossRefPubMed
5.
go back to reference Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.CrossRefPubMed Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.CrossRefPubMed
6.
go back to reference IIanne-Parikka P, Eriksson JG, Lindstrom J, et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish diabetes prevention study. Diabetes Care. 2008;31:805–7.CrossRef IIanne-Parikka P, Eriksson JG, Lindstrom J, et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish diabetes prevention study. Diabetes Care. 2008;31:805–7.CrossRef
7.
go back to reference Arafah M, Al-Hinai AT, Al Mahmeed WA, et al. Centralized pan-middle east survey on the undertreatment of hypercholesterolemia: results From the CEPHEUS study in Arabian Gulf countries. Angiology. 2014;65:919–26.CrossRefPubMed Arafah M, Al-Hinai AT, Al Mahmeed WA, et al. Centralized pan-middle east survey on the undertreatment of hypercholesterolemia: results From the CEPHEUS study in Arabian Gulf countries. Angiology. 2014;65:919–26.CrossRefPubMed
8.
go back to reference Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1. Executive summary. J Clin Lipidol. 2014;8:473–88.CrossRefPubMed Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1. Executive summary. J Clin Lipidol. 2014;8:473–88.CrossRefPubMed
9.
go back to reference Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.CrossRefPubMed Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.CrossRefPubMed
10.
go back to reference James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.CrossRefPubMed James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.CrossRefPubMed
11.
go back to reference Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med. 1993;44:121–31.CrossRefPubMed Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med. 1993;44:121–31.CrossRefPubMed
13.
go back to reference Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 1992;70:733–7.CrossRefPubMed Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 1992;70:733–7.CrossRefPubMed
14.
go back to reference Austin MA. Plasma triglyceride as a risk factor for cardiovascular disease. Can J Cardiol. 1998;14(Suppl B):14B–7B.PubMed Austin MA. Plasma triglyceride as a risk factor for cardiovascular disease. Can J Cardiol. 1998;14(Suppl B):14B–7B.PubMed
15.
go back to reference Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8–15.CrossRefPubMed Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8–15.CrossRefPubMed
16.
go back to reference Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk. A systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113–32.CrossRefPubMed Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk. A systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113–32.CrossRefPubMed
17.
go back to reference Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am Heart J. 1991;121:1283–8.CrossRefPubMed Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am Heart J. 1991;121:1283–8.CrossRefPubMed
18.
go back to reference Lamarche B, Tchernof AG, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec cardiovascular study. Circulation. 1997;95:69–75.CrossRefPubMed Lamarche B, Tchernof AG, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec cardiovascular study. Circulation. 1997;95:69–75.CrossRefPubMed
19.
go back to reference Adeli K, Taghibiglou C, Van Iderstine SC, et al. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med. 2001;11:170–6.CrossRefPubMed Adeli K, Taghibiglou C, Van Iderstine SC, et al. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med. 2001;11:170–6.CrossRefPubMed
20.
go back to reference Karpe F, Tornwall P, Olivecrona T, et al. Composition of human low density: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein. Atherosclerosis. 1993;98:33–49.CrossRefPubMed Karpe F, Tornwall P, Olivecrona T, et al. Composition of human low density: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein. Atherosclerosis. 1993;98:33–49.CrossRefPubMed
21.
go back to reference Mudd JO, Borlaug BA, Johnston PV, et al. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol. 2007;50:173541.CrossRef Mudd JO, Borlaug BA, Johnston PV, et al. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol. 2007;50:173541.CrossRef
22.
go back to reference Tato F, Vega GL, Grundy SM. Determinants of plasma HDL-cholesterol in hypertriglyceridemic patients: role of cholesterol-ester-transfer protein and lecithin cholesteryl acyl transferase. Arterioscler Tromb Vasc Biol. 1997;17:35.CrossRef Tato F, Vega GL, Grundy SM. Determinants of plasma HDL-cholesterol in hypertriglyceridemic patients: role of cholesterol-ester-transfer protein and lecithin cholesteryl acyl transferase. Arterioscler Tromb Vasc Biol. 1997;17:35.CrossRef
23.
go back to reference Ginsberg HN. Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes. 1996;45(Suppl3):S27–30.CrossRefPubMed Ginsberg HN. Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes. 1996;45(Suppl3):S27–30.CrossRefPubMed
24.
go back to reference Festa A, D’Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation. 2000;102:42–7.CrossRefPubMed Festa A, D’Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation. 2000;102:42–7.CrossRefPubMed
25.
go back to reference Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the cardiovascular health study. Diabetes. 2001;50:2384–9.CrossRefPubMed Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the cardiovascular health study. Diabetes. 2001;50:2384–9.CrossRefPubMed
26.
go back to reference Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–34.CrossRefPubMed Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–34.CrossRefPubMed
27.
go back to reference Ridker PM, Buring JE, Cook NR, Rifai N. Creactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation. 2003;107:391397. Ridker PM, Buring JE, Cook NR, Rifai N. Creactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation. 2003;107:391397.
28.
go back to reference Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2012;59:63543.CrossRef Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2012;59:63543.CrossRef
29.
go back to reference Panel ED, Grundy SM. An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia. J Clin Lipid. 2014;8:2960. Panel ED, Grundy SM. An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia. J Clin Lipid. 2014;8:2960.
30.
go back to reference Reiner Z, Catapano AL, DeBacker G, et al. ESC/EAS guidelines for the management of dyslipidemias—The task force for the management of dyslipidemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769e818. Reiner Z, Catapano AL, DeBacker G, et al. ESC/EAS guidelines for the management of dyslipidemias—The task force for the management of dyslipidemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769e818.
31.
go back to reference American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care. 2014;37(Suppl 1):S14–80.CrossRef American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care. 2014;37(Suppl 1):S14–80.CrossRef
32.
go back to reference Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the treating to new targets study. Lancet. 2006;368:919e28.CrossRef Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the treating to new targets study. Lancet. 2006;368:919e28.CrossRef
33.
go back to reference Pyorala K, Ballantyne CM, Gumbiner B, et al. Reduction of cardiovascular events by simavastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 2004;27:1735e40.CrossRef Pyorala K, Ballantyne CM, Gumbiner B, et al. Reduction of cardiovascular events by simavastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 2004;27:1735e40.CrossRef
34.
go back to reference Downs JR, Clearfield M, Weis S, et al. For the Air Force/Texas Coronary Atherosclerosis Prevention Study—primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–22.CrossRefPubMed Downs JR, Clearfield M, Weis S, et al. For the Air Force/Texas Coronary Atherosclerosis Prevention Study—primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–22.CrossRefPubMed
35.
go back to reference Ridker PM; JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003;108:2292–7.CrossRef Ridker PM; JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003;108:2292–7.CrossRef
36.
go back to reference Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.CrossRefPubMed Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.CrossRefPubMed
37.
go back to reference Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ. 2014;349:4379.CrossRef Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ. 2014;349:4379.CrossRef
38.
go back to reference Robins SJ, Bloomfield HE. Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. Curr Opin Lipidol. 2006;17:431–9.PubMed Robins SJ, Bloomfield HE. Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. Curr Opin Lipidol. 2006;17:431–9.PubMed
39.
go back to reference Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;363:692–4.CrossRefPubMed Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;363:692–4.CrossRefPubMed
40.
go back to reference Wang F, Ye P, Hu D, Min Y, Zhao S, Wang Y, et al. Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: a subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China). Atherosclerosis. 2014;237:99e105. Wang F, Ye P, Hu D, Min Y, Zhao S, Wang Y, et al. Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: a subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China). Atherosclerosis. 2014;237:99e105.
41.
go back to reference Chen CY, Chuang SY, Fang CC, et al. Gender disparities in optimal lipid control among patients with coronary artery disease. J Atheroscler Thromb. 2014;21:20–8.CrossRef Chen CY, Chuang SY, Fang CC, et al. Gender disparities in optimal lipid control among patients with coronary artery disease. J Atheroscler Thromb. 2014;21:20–8.CrossRef
42.
go back to reference Faharani P. Gender gap in lipid management amongst diabetes population: an observation. J Popul Ther Clin Pharmacol. 2014;21:181–4. Faharani P. Gender gap in lipid management amongst diabetes population: an observation. J Popul Ther Clin Pharmacol. 2014;21:181–4.
43.
go back to reference Magee MF, Tamis-Holland JE, Lu J, et al. Sex, prescribing practices and guideline recommended, blood pressure, and LDL cholesterol targets at baseline in the BARI 2D trial. Int J Endocrinol. 2015;2015:610239.CrossRefPubMedPubMedCentral Magee MF, Tamis-Holland JE, Lu J, et al. Sex, prescribing practices and guideline recommended, blood pressure, and LDL cholesterol targets at baseline in the BARI 2D trial. Int J Endocrinol. 2015;2015:610239.CrossRefPubMedPubMedCentral
Metadata
Title
Impact of metabolic syndrome on lipid target achievements in the Arabian Gulf: findings from the CEPHEUS study
Authors
Ibrahim Al-Zakwani
Wael Al Mahmeed
Abdullah Shehab
Mohamed Arafah
Ali T. Al-Hinai
Omer Al Tamimi
Mahmoud Al Awadhi
Shorook Al Herz
Faisal Al Anazi
Khalid Al Nemer
Othman Metwally
Akram Alkhadra
Mohammed Fakhry
Hossam Elghetany
Abdel Razak Medani
Afzal Hussein Yusufali
Obaid Al Jassim
Omar Al Hallaq
Fahad Omar Ahmed S. Baslaib
Haitham Amin
Khalid Al-Waili
Khamis Al-Hashmi
Raul D. Santos
Khalid Al-Rasadi
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2016
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-016-0160-6

Other articles of this Issue 1/2016

Diabetology & Metabolic Syndrome 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.